特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界の前立腺癌治療薬市場の見通し

Prostate Cancer - Global Market Outlook (2017-2026)

発行 Stratistics Market Research Consulting 商品コード 531889
出版日 ページ情報 英文 155 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=107.84円で換算しております。
世界の前立腺癌治療薬市場の見通し Prostate Cancer - Global Market Outlook (2017-2026)
出版日: 2019年08月19日 ページ情報: 英文 155 Pages
概要

当レポートでは、世界の前立腺癌治療薬市場について調査分析を行い、市場概要、市場動向などについて考察するとともに、薬剤クラス別、流通チャネル別、地域別に市場を分析、主な企業のプロファイルなどについて包括的にまとめています。

第1章 エグゼクティブサマリー

第2章 イントロダクション

第3章 市場動向分析

  • イントロダクション
  • 促進因子
  • 抑制因子
  • 機会
  • 脅威
  • 新興市場
  • 今後の市場シナリオ

第4章 ファイブフォース分析

  • 供給企業の交渉力
  • 買い手の交渉力
  • 代替品の脅威
  • 新規参入業者の脅威
  • 競争企業間の敵対関係

第5章 世界の前立腺癌治療薬市場:薬剤クラス別

  • イントロダクション
  • 化学療法
  • 標的療法
  • ホルモン治療
  • 免疫療法

第6章 世界の前立腺癌治療薬市場:流通チャネル別

  • イントロダクション
  • 病院内薬局
  • 薬局
  • オンライン
  • その他

第7章 世界の前立腺癌治療薬市場:地域別

  • 北米
  • 欧州
  • アジア太平洋地域
  • 世界のその他の諸国

第8章 主な発展

  • 契約、パートナーシップ、提携、共同事業
  • M&A
  • 新製品発売
  • 拡大
  • その他の主な戦略

第9章 企業プロファイル

図表

List of Tables

  • 1 Global Prostate Cancer Market Outlook, By Region (2016-2026) (US $MN)
  • 2 Global Prostate Cancer Market Outlook, By Type (2016-2026) (US $MN)
  • 3 Global Prostate Cancer Market Outlook, By Hormone Sensitive (2016-2026) (US $MN)
  • 4 Global Prostate Cancer Market Outlook, By Hormone Refractory (2016-2026) (US $MN)
  • 5 Global Prostate Cancer Market Outlook, By Therapy (2016-2026) (US $MN)
  • 6 Global Prostate Cancer Market Outlook, By Focal Therapies (2016-2026) (US $MN)
  • 7 Global Prostate Cancer Market Outlook, By Biologic Therapy (2016-2026) (US $MN)
  • 8 Global Prostate Cancer Market Outlook, By Cryosurgery (2016-2026) (US $MN)
  • 9 Global Prostate Cancer Market Outlook, By Immunotherapy (2016-2026) (US $MN)
  • 10 Global Prostate Cancer Market Outlook, By Vaccines (2016-2026) (US $MN)
  • 11 Global Prostate Cancer Market Outlook, By Therapeutic Vaccines (2016-2026) (US $MN)
  • 12 Global Prostate Cancer Market Outlook, By Provenge (Sipuleucel-T) (2016-2026) (US $MN)
  • 13 Global Prostate Cancer Market Outlook, By Radiation Therapy (2016-2026) (US $MN)
  • 14 Global Prostate Cancer Market Outlook, By External Beam (2016-2026) (US $MN)
  • 15 Global Prostate Cancer Market Outlook, By Brachytherapy (2016-2026) (US $MN)
  • 16 Global Prostate Cancer Market Outlook, By Chemotherapy (2016-2026) (US $MN)
  • 17 Global Prostate Cancer Market Outlook, By Vinorelbine (2016-2026) (US $MN)
  • 18 Global Prostate Cancer Market Outlook, By Vinblastine (2016-2026) (US $MN)
  • 19 Global Prostate Cancer Market Outlook, By Taxotere (Docetaxel) (2016-2026) (US $MN)
  • 20 Global Prostate Cancer Market Outlook, By Taxanes (2016-2026) (US $MN)
  • 21 Global Prostate Cancer Market Outlook, By Jevtana (Cabazitaxel) (2016-2026) (US $MN)
  • 22 Global Prostate Cancer Market Outlook, By Etoposide (2016-2026) (US $MN)
  • 23 Global Prostate Cancer Market Outlook, By Cytotoxic Drugs (2016-2026) (US $MN)
  • 24 Global Prostate Cancer Market Outlook, By Carboplatin (2016-2026) (US $MN)
  • 25 Global Prostate Cancer Market Outlook, By Antimetabolites (2016-2026) (US $MN)
  • 26 Global Prostate Cancer Market Outlook, By Anthracyclines (2016-2026) (US $MN)
  • 27 Global Prostate Cancer Market Outlook, By Alkylating Agents (2016-2026) (US $MN)
  • 28 Global Prostate Cancer Market Outlook, By Surgery (2016-2026) (US $MN)
  • 29 Global Prostate Cancer Market Outlook, By Trans Urethral Resection (TUR) (2016-2026) (US $MN)
  • 30 Global Prostate Cancer Market Outlook, By Radical Prostatectomy (2016-2026) (US $MN)
  • 31 Global Prostate Cancer Market Outlook, By Orchidectomy (2016-2026) (US $MN)
  • 32 Global Prostate Cancer Market Outlook, By Targeted Therapy (2016-2026) (US $MN)
  • 33 Global Prostate Cancer Market Outlook, By Tyrosine Kinase Inhibitors (2016-2026) (US $MN)
  • 34 Global Prostate Cancer Market Outlook, By Signal Transduction Inhibitor (2016-2026) (US $MN)
  • 35 Global Prostate Cancer Market Outlook, By Monoclonal Antibodies (2016-2026) (US $MN)
  • 36 Global Prostate Cancer Market Outlook, By Apoptosis Inducing Drugs (2016-2026) (US $MN)
  • 37 Global Prostate Cancer Market Outlook, By Angiogenesis Inhibitor (2016-2026) (US $MN)
  • 38 Global Prostate Cancer Market Outlook, By Bone Metastasis (2016-2026) (US $MN)
  • 39 Global Prostate Cancer Market Outlook, By Zometa (Zoledronic Acid) (2016-2026) (US $MN)
  • 40 Global Prostate Cancer Market Outlook, By Xofigo (Radium 223 Dichloride) (2016-2026) (US $MN)
  • 41 Global Prostate Cancer Market Outlook, By Xgeva (Denosumab) (2016-2026) (US $MN)
  • 42 Global Prostate Cancer Market Outlook, By Alpharadin (2016-2026) (US $MN)
  • 43 Global Prostate Cancer Market Outlook, By Hormonal Therapy (2016-2026) (US $MN)
  • 44 Global Prostate Cancer Market Outlook, By Aromatase Inhibitors (2016-2026) (US $MN)
  • 45 Global Prostate Cancer Market Outlook, By Estrogen-Receptor Modulators (Serms) (2016-2026) (US $MN)
  • 46 Global Prostate Cancer Market Outlook, By Luteinizing Hormone-Releasing Hormone (LHRH) Analogs (2016-2026) (US $MN)
  • 47 Global Prostate Cancer Market Outlook, By Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists (2016-2026) (US $MN)
  • 48 Global Prostate Cancer Market Outlook, By Anti-Androgens (2016-2026) (US $MN)
  • 49 Global Prostate Cancer Market Outlook, By Other Hormonal Therapies (2016-2026) (US $MN)
  • 50 Global Prostate Cancer Market Outlook, By Diagnostic Technique (2016-2026) (US $MN)
  • 51 Global Prostate Cancer Market Outlook, By Prostate Specific Antigen Test (PSA) (2016-2026) (US $MN)
  • 52 Global Prostate Cancer Market Outlook, By Digital Rectal Exam (DRE) (2016-2026) (US $MN)
  • 53 Global Prostate Cancer Market Outlook, By End User (2016-2026) (US $MN)
  • 54 Global Prostate Cancer Market Outlook, By Ambulatory Surgical Centers (2016-2026) (US $MN)
  • 55 Global Prostate Cancer Market Outlook, By Hospitals (2016-2026) (US $MN)
  • 56 Global Prostate Cancer Market Outlook, By Pharmacies (2016-2026) (US $MN)
  • 57 Global Prostate Cancer Market Outlook, By Specialty Clinics (2016-2026) (US $MN)
  • 58 Global Prostate Cancer Market Outlook, By Other End Users (2016-2026) (US $MN)

NOTE: Tables for North America, Europe, Asia Pacific, South America and Middle East & Africa are represented in the same manner above.

目次

According to Stratistics MRC, the Global Prostate Cancer market is growing at a CAGR of 10.3% during the forecast period. Some of the key factors such as improved diagnosis and frequency rates in industrial economies, rapidly growing geriatric population, and the high demand for effective treatments are propelling the market growth. However, high price for treatment, lack of awareness and short accessibility of health care services in the small regions which are hampering the growth of the market.

Prostate cancer is one of the most ordinary types of cancer in men which is caused by the irregular growth of tissues in the prostate gland that produce seminal fluid. Various types of prostate cancer grow up slowly and may require minimal or no treatment, other types are hostile and can increase quickly. This needs novel drugs that will address the unmet desires low cost and enhanced survival time.

Based on Therapy, Biologic therapy is a treatment for patients with prostate cancer that involves utilize of existing organisms, substances plagiaristic from living organisms, or laboratory formed versions of living organisms. Biological therapies use diverse ways to rouse the immune system and stop tumor cells from rising. For patients with cancer, biological therapies may be used to treat the cancer itself or the side effects of other cancer treatments.

By Geography, Asia Pacific is expected to exhibit the utmost growth on account of the existence of untapped opportunity in the rising economies such as India and China. As well, rising healthcare expenditure has caused an increase in the implementation of technically advanced commodities, which is likely to boost county market growth.

Some of the key players profiled in the Prostate Cancer Market include Astellas, Inc., AstraZeneca plc, Bristol Myers Squibb (BMS), Johnson & Johnson, NOVARTIS, Sanofi S.A, TOLMAR Inc., Tokai Pharmaceuticals, Progenics Pharmaceuticals Inc., OncoGenex Pharmaceuticals Inc., OncBioMune Pharmaceuticals Inc., Endo Pharmaceuticals, and Bayer Pharma AG.

Types Covered:

  • Hormone Sensitive
  • Hormone Refractory

Therapies Covered:

  • Focal Therapies
  • Biologic Therapy
  • Cryosurgery
  • Immunotherapy
  • Therapeutic Vaccines
  • Radiation Therapy
  • Chemotherapy
  • Surgery
  • Targeted Therapy
  • Bone Metastasis
  • Hormonal Therapy

Diagnostic Techniques Covered:

  • Prostate Specific Antigen Test (PSA)
  • Digital Rectal Exam (DRE)

End Users Covered:

  • Ambulatory Surgical Centers
  • Hospitals
  • Pharmacies
  • Specialty Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country level segments
  • Market share analysis of the top industry players
  • Strategic recommendations for the new entrants
  • Market forecasts for a minimum of 9 years of all the mentioned segments, sub-segments, and the regional markets
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the clients interest (Note: Depends of feasibility check)
  • Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Futuristic Market Scenario

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Prostate Cancer Market, By Type

  • 5.1 Introduction
  • 5.2 Hormone Sensitive
  • 5.3 Hormone Refractory

6 Global Prostate Cancer Market, By Therapy

  • 6.1 Introduction
  • 6.2 Focal Therapies
  • 6.3 Biologic Therapy
  • 6.4 Cryosurgery
  • 6.5 Immunotherapy
    • 6.5.1 Vaccines
  • 6.6 Therapeutic Vaccines
    • 6.6.1 Provenge (Sipuleucel-T)
  • 6.7 Radiation Therapy
    • 6.7.1 External Beam
      • 6.7.1.1 Stereotactic Body
      • 6.7.1.2 Proton Beam
      • 6.7.1.3 Intensity Modulated
      • 6.7.1.4 3D Conformal
    • 6.7.2 Brachytherapy
      • 6.7.2.1 Temporary
      • 6.7.2.2 Permanent
  • 6.8 Chemotherapy
    • 6.8.1 Vinorelbine
    • 6.8.2 Vinblastine
    • 6.8.3 Taxotere (Docetaxel)
    • 6.8.4 Taxanes
    • 6.8.5 Jevtana (Cabazitaxel)
    • 6.8.6 Etoposide
    • 6.8.7 Cytotoxic Drugs
    • 6.8.8 Carboplatin
    • 6.8.9 Antimetabolites
    • 6.8.10 Anthracyclines
    • 6.8.11 Alkylating Agents
  • 6.9 Surgery
    • 6.9.1 Trans Urethral Resection (TUR)
    • 6.9.2 Radical Prostatectomy
    • 6.9.3 Orchidectomy
  • 6.10 Targeted Therapy
    • 6.10.1 Tyrosine Kinase Inhibitors
    • 6.10.2 Signal Transduction Inhibitor
    • 6.10.3 Monoclonal Antibodies
    • 6.10.4 Apoptosis Inducing Drugs
    • 6.10.5 Angiogenesis Inhibitor
  • 6.11 Bone Metastasis
    • 6.11.1 Zometa (Zoledronic Acid)
    • 6.11.2 Xofigo (Radium 223 Dichloride)
    • 6.11.3 Xgeva (Denosumab)
    • 6.11.4 Alpharadin
  • 6.12 Hormonal Therapy
    • 6.12.1 Aromatase Inhibitors
    • 6.12.2 Estrogen-Receptor Modulators (Serms)
    • 6.12.3 Luteinizing Hormone-Releasing Hormone (LHRH) Analogs
      • 6.12.3.1 Lupron
      • 6.12.3.2 Zoladex
      • 6.12.3.3 Decapeptyl
      • 6.12.3.4 Eligard
      • 6.12.3.5 Vantas
      • 6.12.3.6 Leuplin
      • 6.12.3.7 Trelstar (Triptorelin Pamoate)
      • 6.12.3.8 Firmagon (Degarelix)
      • 6.12.3.9 Casodex (Bicalutamide)
    • 6.12.4 Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
      • 6.12.4.1 Zytiga
      • 6.12.4.2 Gonax
      • 6.12.4.3 Xtandi (Enzalutamide)
    • 6.12.5 Anti-Androgens
      • 6.12.5.1 Casodex
      • 6.12.5.2 Xtandi or MDV3100
      • 6.12.5.3 Xtandi US or MDV3100
    • 6.12.6 Other Hormonal Therapies

7 Global Prostate Cancer Market, By Diagnostic Technique

  • 7.1 Introduction
  • 7.2 Prostate Specific Antigen Test (PSA)
  • 7.3 Digital Rectal Exam (DRE)

8 Global Prostate Cancer Market, By End User

  • 8.1 Introduction
  • 8.2 Ambulatory Surgical Centers
  • 8.3 Hospitals
  • 8.4 Pharmacies
  • 8.5 Specialty Clinics
  • 8.6 Other End Users

9 Global Prostate Cancer Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Astellas, Inc.
  • 11.2 AstraZeneca plc
  • 11.3 Bristol Myers Squibb (BMS)
  • 11.4 Johnson & Johnson
  • 11.5 NOVARTIS
  • 11.6 Sanofi S.A
  • 11.7 TOLMAR Inc.
  • 11.8 Tokai Pharmaceuticals
  • 11.9 Progenics Pharmaceuticals Inc.
  • 11.10 OncoGenex Pharmaceuticals Inc.
  • 11.11 OncBioMune Pharmaceuticals Inc.
  • 11.12 Endo Pharmaceuticals
  • 11.13 Bayer Pharma AG